Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling

After Taxotere fails, treatment options for metastatic prostate cancer are limited. The three drugs with FDA approval in this setting, Jevtana, Provenge and Zytiga, are associated with median survivals of less than 2 years. In part, the impact on survival is the result of low response rates, indicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Charles E., Basu, Gargi, Wright, Brian, Mahanes, Joanne, Spinelli, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Published online: March, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364088/
https://www.ncbi.nlm.nih.gov/pubmed/22666205
http://dx.doi.org/10.1159/000338077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364088/
https://www.ncbi.nlm.nih.gov/pubmed/22666205
http://dx.doi.org/10.1159/000338077

Ejemplares similares